This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Oct 25;379(17):1671-1672.

doi: 10.1056/NEJMe1811996. Epub 2018 Oct 18.

Triple CFTR Modulator Therapy for Cystic Fibrosis

Fernando Holguin¹

Affiliations

PMID: 30334694
DOI: 10.1056/NEJMe1811996

Editorial

Triple CFTR Modulator Therapy for Cystic Fibrosis

Fernando Holguin. N Engl J Med. 2018.

. 2018 Oct 25;379(17):1671-1672.

doi: 10.1056/NEJMe1811996. Epub 2018 Oct 18.

Author

Fernando Holguin¹

Affiliation

¹ From the Division of Pulmonary Sciences and Critical Care, University of Colorado, Aurora.

PMID: 30334694
DOI: 10.1056/NEJMe1811996

No abstract available

PubMed Disclaimer

Comment on

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group. Davies JC, et al. N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18. N Engl J Med. 2018. PMID: 30334693 Free PMC article. Clinical Trial.

Similar articles

CFTR mutations and cystic fibrosis.
[No authors listed] [No authors listed] Prescrire Int. 2013 Oct;22(142):232. Prescrire Int. 2013. PMID: 24298580 No abstract available.
Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation.
McGarry ME. McGarry ME. N Engl J Med. 2020 Feb 13;382(7):684. doi: 10.1056/NEJMc1916747. N Engl J Med. 2020. PMID: 32053310 No abstract available.
A little CFTR can change a lot: slowing cystic fibrosis progression.
Rowe SM. Rowe SM. Lancet Respir Med. 2017 Feb;5(2):86-87. doi: 10.1016/S2213-2600(16)30465-9. Epub 2016 Dec 21. Lancet Respir Med. 2017. PMID: 28011036 No abstract available.
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS. Pettit RS. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26. Ann Pharmacother. 2012. PMID: 22739718 Review.
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H, Ma T. Yang H, et al. Expert Opin Ther Pat. 2015;25(9):991-1002. doi: 10.1517/13543776.2015.1045878. Epub 2015 May 15. Expert Opin Ther Pat. 2015. PMID: 25971311 Review.

See all similar articles

Cited by

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.
Li C, Liu Z, Anderson J, Liu Z, Tang L, Li Y, Peng N, Chen J, Liu X, Fu L, Townes TM, Rowe SM, Bedwell DM, Guimbellot J, Zhao R. Li C, et al. PLoS One. 2023 Nov 29;18(11):e0295009. doi: 10.1371/journal.pone.0295009. eCollection 2023. PLoS One. 2023. PMID: 38019847 Free PMC article.
Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators.
Francalanci M, Terlizzi V, Fevola C, Di Rosa G, Pierattini V, Roselli E, Bonomi P, Cavicchi MC, Galici V, Neri AS, Bianchimani C, Campana S, Dolce D, Ravenni N, Camera E, Orioli T, Taccetti G. Francalanci M, et al. Children (Basel). 2023 Jan 30;10(2):252. doi: 10.3390/children10020252. Children (Basel). 2023. PMID: 36832382 Free PMC article.
A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.
Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A. Zaher A, et al. Cureus. 2021 Jul 3;13(7):e16144. doi: 10.7759/cureus.16144. eCollection 2021 Jul. Cureus. 2021. PMID: 34268058 Free PMC article. Review.
Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor.
Arnaud F, Stremler-Le Bel N, Reynaud-Gaubert M, Mancini J, Gaubert JY, Gorincour G. Arnaud F, et al. J Clin Med. 2021 May 7;10(9):1999. doi: 10.3390/jcm10091999. J Clin Med. 2021. PMID: 34066942 Free PMC article.
Changes in fecal microbiota with CFTR modulator therapy: A pilot study.
Pope CE, Vo AT, Hayden HS, Weiss EJ, Durfey S, McNamara S, Ratjen A, Grogan B, Carter S, Nay L, Parsek MR, Singh PK, McKone EF, Aitken ML, Rosenfeld MR, Hoffman LR. Pope CE, et al. J Cyst Fibros. 2021 Sep;20(5):742-746. doi: 10.1016/j.jcf.2020.12.002. Epub 2020 Dec 31. J Cyst Fibros. 2021. PMID: 33390317 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- Genetic Alliance
- MedlinePlus Health Information